Weeks after the FDA rejected Veru’s emergency use authorization bid for sabizabulin in COVID-19, the company announced plans to continue with late-stage development of the drug.
https://www.pharmalive.com/wp-content/uploads/2022/05/US-Bridging-Study-Not-Enough-as-FDA-Denies-Hutchmeds-Pancreatic-Cancer-Drug-BioSpace-5-2-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-03-15 09:26:202023-03-15 09:27:29Veru moves forward with late-stage COVID study despite FDA roadblock
